Tumor suppressor Inc-CTSLP4 inhibits EMT and metastasis of gastric cancer by attenuating HNRNPAB-dependent Snail transcription

Tao Pan,1,3 Zhenjia Yu,1,3 Zhijian Jin,1,3 Xiongyan Wu,1 Airong Wu,2 Junyi Hou,1 Xinyu Chang,1 Zhiyuan Fan,1 Jianfang Li,1 Beiqin Yu,1 Fangyuan Li,1 Chao Yan,1 Zhongyin Yang,1 Zhenggang Zhu,1 Bingya Liu,1 and Liping Su1

INTRODUCTION
Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-related death worldwide, with particularly high mortality and morbidity in China.1–3 Approximately 50% of GC patients present with metastases, and the 5-year overall survival (OS) rate of these patients is no more than 25%.3,4 Tumor metastasis is a crucial impediment to the successful treatment for GC; however, the mechanisms underlying GC metastasis have yet to be comprehensively elucidated.6 The epithelial-to-mesenchymal transition (EMT) program is a developmental process hijacked by cancer cells to facilitate their dissemination and metastatic cascade,6 during which epithelial cells progressively lose their cell identity and acquire a mesenchymal phenotype.8 Aberrant activation of EMT has been shown to play a key role in tumor metastatic cascade. Thus, understanding the molecular regulation of EMT is critical for elucidating the mechanism of GC metastasis and designing new therapeutic strategies.

Molecular networks involving the regulation of the EMT program are highly complicated, including various extracellular stimuli, classical growth factors, and other signaling pathways including Wnt, Notch, JAK-STAT, and nuclear factor κB (NF-κB).9 In response to these EMT-inducing pathways, a majority of EMT-inducing transcription factors (EMT-TFs), including SNAIL family (Slug, Snail, and Smuc), Twist, and ZEB family (ZEB1 and ZEB2), are activated to orchestrate the EMT program. Among these EMT-TFs, Snail is a zinc finger TF and is first described in Drosophila melanogaster.10 As a critical transcriptional repressor of E-cadherin expression, Snail plays an important role in the developmental and oncogenic EMT program.11,12 Recent studies have revealed that the expression of Snail is regulated by a complex signaling network at the transcriptional and post-translational level, and various signaling molecules within the tumor microenvironment, such as transforming growth factor beta (TGF-β), epidermal growth factor (EGF), tumor necrosis factor alpha (TNF-α), and fibroblast growth factor (FGF), have been shown to induce Snail expression in different cellular contexts. Snail protein stability, subcellular localization, and activity are regulated by various post-translational modifications, including phosphorylation, ubiquitination, and lysine oxidation.13 Notably, long non-coding RNAs (lncRNAs), eukaryotic cell genome-encoded transcripts of more
Lnc-CTSLP4 expression is downregulated in tumor tissues and inversely associated with the prognosis of GC patients

We have previously discovered that lnc-CTSLP4 is obviously dysregulated in GC. To identify the levels of lnc-CTSLP4 in GC, tumor tissues and adjacent non-tumor tissues from 43 GC patients (GC cohort 1) were subjected to qRT-PCR assays, and the results showed that the expression of lnc-CTSLP4 was decreased in 77% of GC tumor tissues (Figure 1A). Notably, lnc-CTSLP4 expression was significantly lower in GC tumor tissues than that in the adjacent non-tumor tissues (Figure 1B). We performed rapid amplification of cDNA ends (RACE) to identify the full sequence of lnc-CTSLP4 in GC cells (Figures S1A–S1F), and the protein-coding potential of lnc-CTSLP4 was predicted according to the CPC2 website (http://cpc2.gao-lab.org/) and CPAT website (http://lilab.research.bcm.edu/cpat/index.php; Figure 1C), which confirmed that lnc-CTSLP4 was affiliated to the non-coding RNA class. Furthermore, we checked lnc-CTSLP4 expression in 157 GC patients (GC cohort 2) by RNA-fluorescence in situ hybridization (RNA-FISH), and the results showed that lnc-CTSLP4 high expression rate was lower in GC tumor tissues (18.0%, 28 of 157) than that in adjacent non-tumor tissues (62%, 97 of 157; Figures 1D and 1E). In addition, we demonstrated that the expression of lnc-CTSLP4 was correlated with local invasion, lymph node metastasis, and TNM stage (Table 1; Figures S2A and S2B). Our data also revealed that low expression level of lnc-CTSLP4 in GC tumor tissues was positively correlated with shorter survival for patients with GC significantly (Figure 1F). Univariate analysis indicated that lnc-CTSLP4 expression in GC tumor tissues (hazard ratio (HR) = 3.819, 95% confidence interval [CI] [1.386–10.522], p = 0.01) was related to OS of GC patients (Figure 1G). Multivariate Cox analysis indicated that lnc-CTSLP4 expression in GC tumor tissues (HR = 2.922, 95% CI [1.041–8.198], p = 0.042) was an independent prognostic risk factor related to OS (Figure 1H). Consistent with the downregulated expression of lnc-CTSLP4 expression in GC tumor tissues, GC cell lines also expressed relatively low levels of lnc-CTSLP4 compared with a normal gastric epithelium cell line, GES-1 (Figure 1I). To further define the cellular localization of lnc-CTSLP4 in GC cells, qRT-PCR and RNA-FISH were performed, and the results showed that lnc-CTSLP4 localized in both cytoplasm and nucleus of GC cells (HGC27 and MGC803, Figures 1J and 1K). Taken together, these results suggest that downregulated lnc-CTSLP4 is associated with the aggressive progression of GC, and lnc-CTSLP4 could be a potential prognostic indicator for patients with GC.

Figure 1. Lnc-CTSLP4 expression is downregulated in tumor tissues and inversely associated with the prognosis of GC patients
(A) The expression of lnc-CTSLP4 in 43 GC tissues (GC cohort 1, the ratio of GC tumor tissues versus adjacent non-tumor tissues [–ΔCt]). (B) Expression levels of lnc-CTSLP4 in GC tumor tissues (GC cohort 1) and adjacent normal tissues (–ΔCt, *p < 0.05, **p < 0.01, ***p < 0.001). (C) The coding ability of lnc-CTSLP4 calculated by CPC2 and CPAT. (D) RNA-FISH analysis of lnc-CTSLP4 expression in the paraffin-embedded GC tumor tissues and adjacent non-tumor tissues (red: lnc-CTSLP4; blue: DAPI). (E) Kaplan–Meier analysis of the overall survival of GC (GC cohort 2, n = 157). The log-rank test revealed statistical significance between the low lnc-CTSLP4 expression group (n = 129) and the high lnc-CTSLP4 expression group (n = 28). (F and H) Univariate (F) and multivariate (H) analysis for prognostic features of GC patients (n = 157). (I) Expression of lnc-CTSLP4 in the subcellular fractions of GC cells (MGC803 and HGC27, qRT-PCR; U8 and S14 were used as nuclear and cytoplasmic markers, respectively). (K) Representative RNA-FISH imaging of lnc-CTSLP4 (red) in GC cells (red: lnc-CTSLP4; blue: DAPI; magnification: 200× and 400×).

Table 1. Correlation between the clinicopathological features and expression of lnc-CTSLP4

| Clinicopathologic parameters | Number of cases | Inc-CTSLP4 FISH | p value |
|-----------------------------|----------------|----------------|---------|
| Age (years)                 |                |                |         |
| ≥ 60                        | 89             | 75             | 14      | 0.0431 |
| <60                         | 68             | 54             | 14      | 0.636  |
| Gender                      |                |                |         |
| Male                        | 112            | 91             | 21      |         |
| Female                      | 45             | 38             | 7       |         |
| Tumor size (cm)             |                |                |         |
| ≥ 5                         | 102            | 89             | 13      | 0.023  |
| <5                          | 55             | 40             | 15      |         |
| Local invasion              |                |                |         |
| T1, T2                      | 18             | 9              | 9       | <0.001 |
| T3, T4                      | 139            | 120            | 19      |         |
| Lymph node metastasis       |                |                |         |
| No                          | 27             | 15             | 12      | <0.001 |
| Yes                         | 130            | 114            | 16      |         |
| TNM stage                   |                |                |         |
| I, II                       | 34             | 17             | 17      | <0.001 |
| III, IV                     | 123            | 112            | 11      |         |
Lnc-CTSLP4 overexpression inhibits GC cell EMT, migration, and invasion in vitro

To determine the biological function of Inc-CTSLP4 in the GC cells, we constructed Inc-CTSLP4-overexpressing cells (MGC803-CTSLP4 and AGS-CTSLP4) and Inc-CTSLP4-knockdown cells (HGC27-sh-CTSL4 and MKN28-sh-CTSL4) by transfecting GC cells with Inc-CTSLP4 AV-CTSLP4 or short hairpin RNA (shRNA), respectively (Figures 2A and 2B). EMT, a fundamental cell-biological process during embryonic development and organogenesis, is often hijacked by malignant cells to facilitate their dissemination to distant organs.9,19,20 We first determined whether Inc-CTSLP4 could affect GC cell morphology. GC cells expressing empty vector retained dispersed and mesenchymal properties. In contrast, GC cells overexpressing Inc-CTSLP4 exhibited a typical rounded (or amoeboid-like) morphology and reduction of lamellipodia formation, which indicated that Inc-CTSLP4 could potentially inhibit EMT of GC (Figure 2C). To further investigate the function of Inc-CTSLP4 in GC progression, we conducted PCR-array assays to detect the changed expression of EMT-associated genes in GC cells overexpressing Inc-CTSLP4. The results showed that the expression of Snail, the key EMT-inducing TF, and CDH2 (N-cadherin, the mesenchymal marker) was significantly decreased, and the expression of CDH1 (E-cadherin, the epithelial marker) was remarkably increased when Inc-CTSLP4 was overexpressed (Figure 2D). Consistent with these findings, the expression of E-cadherin, N-cadherin, and Snail in MGC803-AV-CTSLP4 and HGC27-sh-CTSL4 cells was further confirmed by qRT-PCR, Western blot, and immunofluorescence (Figures 2E and 2F; Figures S3A and S3B). We validated the relationship between the Inc-CTSLP4 expression and EMT characters in 157 pairs of GC tumor tissues and adjacent non-tumor tissues, and the results showed that E-cadherin expression (based on immunohistochemistry [IHC] scores) in the low Inc-CTSLP4 expression group was significantly decreased when compared with that in the high Inc-CTSLP4 expression group; N-cadherin expression (based on IHC scores) in the low Inc-CTSLP4 expression group was significantly higher than that in the high Inc-CTSLP4 expression group (Figures 2G–2I). To further examine the effect of aberrant Inc-CTSLP4 expression on GC cell migration and invasion, we performed Transwell assays, and the results revealed that overexpression of Inc-CTSLP4 reduced the migratory and invasive capacity of MGC803-AV-CTSLP4 and AGS-AV-CTSLP4, while knockdown of Inc-CTSLP4 expression led to increased migratory and invasive capacity of HGC27-sh-CTSL4 and MKN28-sh-CTSL4 (Figure 2J). Moreover, wound healing assay confirmed that overexpression of Inc-CTSLP4 markedly reduced cell migration, whereas knockdown of Inc-CTSLP4 had the opposite effect (Figures 2K and 2L). Thus, these data demonstrate that Inc-CTSLP4 overexpression inhibits the metastatic capacity and the EMT program of GC cells.

Lnc-CTSLP4 binds to Hsp90α and promotes the degradation of HNRNPAB protein by recruiting ZFP91

To explore the molecular mechanism and binding partners of Inc-CTSLP4 in GC cells, we performed RNA-pulldown assays with biotin-labeled Inc-CTSLP4 (Inc-CTSLP4 full-length sense and antisense), and the retrieved proteins were subjected to SDS-PAGE electrophoresis and mass spectrum analysis. Hsp90α was identified as a clear binding partner of Inc-CTSLP4 (Figures 3A–3C; Table S1). The specific interaction of Inc-CTSLP4 and Hsp90α was confirmed by Western blot using the proteins isolated from the RNA-pulldown assays (Figure 3D). RNA immunoprecipitation (RIP) assay was performed to confirm that Hsp90α could specifically bind to Inc-CTSLP4 using a specific Hsp90α antibody (Figures 3E and 3F). Hsp90α is known as a molecular chaperone that is essential for maintaining the proper folding and stability of specific target proteins (Hsp90 clients).21 We therefore performed co-immunoprecipitation (Co-IP) analysis with Hsp90α-specific antibody to evaluate binding affinity alterations of Hsp90α and its potential client proteins in MGC803-AV-CON cells and MGC803-AV-CTSLP4 cells, and the retrieved proteins were then subjected to SDS-PAGE electrophoresis and mass spectrum analysis. The results showed that Hsp90α could potentially bind 486 proteins in Inc-CTSLP4-overexpressing GC cells and 479 proteins in the AV-CON GC cells. 263 proteins were identified only in the AV-CON GC cells, and HNRNPAB, a member of ubiquitously expressed heterogeneous nuclear ribonucleoproteins (hnRNPs), was found to bind to Hsp90α in the absence of Inc-CTSLP4 (Figure 3G; Table S2).

To determine whether HNRNPAB requires Hsp90α to maintain its structural stability, Co-IP was performed with Hsp90α- or HNRNPAB-specific antibodies (Figure 3H). The results confirmed that Hsp90α and HNRNPAB formed a complex in MGC803 cells. Glutathione S-transferase (GST)-pulldown experiments were then performed to detect the direct interactions of HNRNPAB and Hsp90α, and the results showed that GST-fused HNRNPAB, but not GST, could pulldown Hsp90α, which confirmed the direct interactions between HNRNPAB and Hsp90α (Figure 3I). Furthermore, the interaction between Hsp90α and HNRNPAB in MGC803 was markedly reduced in MGC803-AV-CTSLP4 (Figure 3J). To confirm that HNRNPAB is a client of Hsp90α, we performed RIP and RNA-pulldown assays to detect the expression of Hsp90α and HNRNPAB in Hsp90α-knockdown GC cells. The results showed that the expression of Hsp90α and HNRNPAB was significantly decreased in Hsp90α-knockdown GC cells, whereas the expression of Hsp90α and HNRNPAB was significantly increased in Hsp90α-overexpression GC cells. These data demonstrate that Hsp90α and HNRNPAB form a complex in GC cells, and overexpression of Inc-CTSLP4 reduces the interaction between Hsp90α and HNRNPAB, thereby inhibiting the degradation of HNRNPAB.

Figure 2. Lnc-CTSLP4 overexpression inhibits GC cell EMT, migration, and invasion in vitro

(A and B) qRT-PCR analysis of Inc-CTSLP4 expression in GC cells after shRNA knockdown (A) or overexpression (B) of Inc-CTSLP4. *p < 0.05, **p < 0.01. (C) Morphological change of GC cells after overexpression of CTSLP4 (100×). (D) PCR-array analysis of EMT-associated genes in MGC803-AV-CTSLP4 and MGC803-AV-CON cells. (E) qRT-PCR analysis of E-cadherin, N-cadherin, and Snail mRNA in GC cells after overexpression or shRNA knockdown of Inc-CTSLP4. **p < 0.01, ***p < 0.001. (F) Western blot analysis of E-cadherin, N-cadherin, and Snail protein in GC cells (MGC803, AGS, HGC27, MKN28 cells) after knockdown of Inc-CTSLP4 (*p < 0.05, **p < 0.01, ***p < 0.001). (G and H) Representative IHC imaging of E-cadherin and N-cadherin (magnification: 25× and 100×). (I) Correlation of Inc-CTSLP4 expression (RNA-FISH) and EMT markers (E-cadherin and N-cadherin, IHC) in GC (GC cohort 2; *p < 0.05, **p < 0.01). (J) The migration and invasion abilities of GC cells after overexpression or knockdown of Inc-CTSLP4 (Transwell assay; **p < 0.01, ***p < 0.001). (K and L) Wound-healing assays of GC cells after transfection with AV-CTSLP4 or sh-CTSLP4 (*p < 0.01, ***p < 0.001, magnification: 200×).
A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

(legend on next page)
of Hsp90, MGC803 cells were exposed to 17-AAG, an Hsp90 inhibitor, for a range of times and doses, and then the expression of HNRNPAB was analyzed. The results verified that upon HSP90 inhibition, the levels of HNRNPAB were reduced (Figure 3K; Figures S4A–S4D). Interestingly, the ubiquitin modification of HNRNPAB in MGC803-CTSLP4 cells was more enhanced than that in controls (Figure 3L). ZFP91 has been reported to regulate HNRNP F (a member of the hnRN family) by its E3 ubiquitin ligase activity. We further performed Co-IP analysis to investigate the potential effect of Inc-CTSLP4 on the interaction of ZFP91 and HNRNPAB; we found that HNRNPAB could bind more ZFP91 and less Hsp90α in Inc-CTSLP4-overexpressing MGC803 cells compared with the control group, which indicated that the HNRNPAB-ZFP91 interaction was increased in GC cells after overexpression of Inc-CTSLP4, coincident with the decreased Hsp90α-HNRNPAB interaction (Figure 3M). RNA-pulldown assays verified that Inc-CTSLP4 could specifically bind to ZFP91 (Figure 3N). We determined the expression levels of HNRNPAB in GC cells and its potential correlation with Inc-CTSLP4 expression levels. The results showed that HNRNPAB protein expression was remarkably downregulated in MGC803-CTSLP4 and AGS-CTSLP4 cells, while it was upregulated in HGC27-sh-CTSLP4 and MKN28-sh-CTSLP4 cells (Figure 3O).

To further identify the site that mediates the interaction between Inc-CTSLP4 and Hsp90α, we predicted RNA-protein interactions and domains using CatRAPID, an online algorithm for estimating the protein-RNA binding propensity based on the secondary structure, hydrogen bonding, and molecular interatomic forces. Two regions (region 1 located around 469–626 bp; region 2 located around 3,065–3,222 bp) of Inc-CTSLP4 exhibited the greatest probability of binding Hsp90α (Figure 3A and 3B). Based on the predicted RNA secondary structure of Inc-CTSLP4 via the RNAfold website (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi; Figures S5C and S5D), we truncated Inc-CTSLP4 into four fragments (Figure 3P). RNA-pulldown assays demonstrated that the Hsp90α-binding activity mapped to 1–1,130 bp of Inc-CTSLP4 (Figure 3Q). Together, these data indicate that HNRNPAB is a new client of Hsp90α, and that Inc-CTSLP4 overexpression attenuates the interaction between HNRNPAB and Hsp90α, which promotes ZFP91-induced HNRNPAB ubiquitination and degradation.

**Lnc-CTSLP4 inhibits EMT via suppressing HNRNPAB-mediated Snail transcriptional activation in GC cells**

HNRNPAB is a member of hnRNPs and has been reported to act as a TF in activating Snail transcription. To better understand how Inc-CTSLP4 regulates GC cell metastatic potential, we considered the possibility that HNRNPAB-mediated Snail transcription and EMT were suppressed by Inc-CTSLP4 in GC cells. The expression of EMT markers was therefore assessed in both HNRNPAB-overexpressing and HNRNPAB-knockdown GC cells. Overexpression of HNRNPAB promoted the protein expression of Snail and N-cadherin and reduced the expression of E-cadherin, while knockdown of HNRNPAB had the reverse effect (Figure 4A). Moreover, chromatin IP (ChIP)-PCR and dual-luciferase reporter assays confirmed that HNRNPAB could bind the Snail promoter (Figure 4B) and induce Snail expression via its ~866 to ~862 bp promoter region (Figures 4C and 4D). To further ascertain whether Inc-CTSLP4 inhibits GC cell EMT by repressing the HNRNPAB/Snail pathway, we performed the rescue experiment. The results showed that the Inc-CTSLP4-mediated suppression of EMT was reversed by HNRNPAB overexpression, while inhibition of Snail expression blocked the HNRNPAB-induced EMT (Figures 4E and 4F). Taken together, these data indicate that Inc-CTSLP4 inhibits GC cell EMT via suppressing HNRNPAB-mediated Snail transcriptional activation.

HNRNPAB is inversely correlated with Inc-CTSLP4 in human GC and rescues the suppressive effects of Inc-CTSLP4 on GC cells

To investigate the relationship between the expression of Inc-CTSLP4 and HNRNPAB in subjects with GC, we analyzed the public database and 157 pairs of human GC tumor tissues and adjacent non-tumor tissues from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The results indicated that HNRNPAB was obviously upregulated in GC tumor tissues (Figures 5A and 5B), which was verified by GEPIA based on The Cancer Genome Atlas (TCGA) and GTex database (http://gepia.cancer-pku.cn) (Figure 5C), and the expression of HNRNPAB in GC tumor tissues was positively correlative with tumor size, local invasion, lymph node metastasis, and TNM stage (Figure 5D; Figures 5A–5D, Table 2). Based on Kaplan-Meier plotter analysis (http://kmplot.com/analysis) and our data, we found that HNRNPAB expression in GC tumor tissues was inversely proportional to the survival time of the patients with GC (Figures 5E–5G; Figures S6D–S6G). Univariate analysis showed that HNRNPAB is inversely correlated with Inc-CTSLP4 and HNRNPAB in GC.
Figure 4. Lnc-CTSLP4 inhibits EMT via suppressing HNRNPAB-mediated Snail transcriptional activation in GC cells

(A) The expression level of E-cadherin, N-cadherin, HNRNPAB, and Snail in MGC803 and HGC27 cells after shRNA knockdown (sh-HNRNPAB) or overexpression (HNRNPAB) of HNRNPAB (**p < 0.01, ***p < 0.001). (B) The binding of HNRNPAB to the Snail promoter in GC cells (ChIP-PCR assays, **p < 0.01, ***p < 0.001). (C and D)

(legend continued on next page)
expression in GC tumor tissues (HR = 2.580, 95% CI [1.371–4.854], p = 0.003) was related to OS in GC patients (Figure 5H). Multivariate analysis indicated that Inc-CTSLP4 expression in GC tumor tissues (hazard ratio (HR) = 2.580, 95% CI [1.371–4.854], p = 0.003) was an independent prognostic risk factor related to OS (Figure 5I). We also analyzed the association of the expression levels of HNRNPAB and Inc-CTSLP4 in GC tissues. We found that the HNRNPAB expression level was higher in the Inc-CTSLP4-low expression group compared with that in the Inc-CTSLP4-high expression group (Figure 5J). Pearson correlation analysis revealed that the expression level of HNRNPAB was correlated with E-cadherin (r = −0.4121, p < 0.001) and N-cadherin (r = 0.7322, p < 0.001) expression, which was verified by GEPIA (Figure 5K–5M). Meanwhile, bioinformatics analysis showed that the expression level of HNRNPAB was positively correlated with Snail expression based on GEPIA (Figure 5N). To further evaluate the biological function of HNRNPAB in GC progression, we performed Transwell assays, and the results revealed that up-regulation of HNRNPAB promoted the migratory and invasive ability of GC cells, while knockdown of HNRNPAB expression inhibited GC cell migration and invasion (Figures 5O–5R). In addition, the inhibition of migratory capacity of GC cells induced by Inc-CTSLP4 was reversed by HNRNPAB, which was dependent on Snail expression (Figures 5S and 5T). Thus, these data demonstrate that HNRNPAB is inversely correlated with lnc-CTSLP4 in human GC and can rescue the suppressive effects of Inc-CTSLP4 on GC cells.

Lnc-CTSLP4 overexpression inhibits tumor growth, invasion, and metastasis in vivo

Next, we examined the effects of Inc-CTSLP4 on tumor growth and metastasis in vivo. MGC803-AV-CON, MGC803-AV-CTSLP4, HGC27-sh-Ctrl, and HGC27-sh-CTSLP4 cells were subcutaneously transplanted into nude mice and tumor growth was monitored. Overexpression of Inc-CTSLP4 resulted in dramatic inhibition of tumor growth, while genetic inhibition of Inc-CTSLP4 led to aggressive progression of tumor size. (Figures 5A–5H). To further verify that Inc-CTSLP4 overexpression attenuates the in vivo metastatic potential of GC cells, MGC803 cells transfected with AV-CTSLP4 or AV-CON were intraperitoneally inoculated into immunodeficient nude mice, and the occurrence of peritoneal metastases was assessed. GC cells transfected with AV-CTSLP4 developed fewer peritoneal metastatic nodules than those transfected with AV-CON (Figures 6A and 6B). The expression of Inc-CTSLP4 was detected in the tumor tissue of the mice model by qRT-PCR. The results showed that Inc-CTSLP4 was significantly upregulated in the AV-CTSLP4 group and downregulated in the sh-CTSLP4 group in comparison with the control group, respectively (Figure 6C). IHC staining revealed that N-cadherin, HNRNPAB, and Snail expression were increased in the sh-CTSLP4 group in comparison with the control group, respectively (Figures 6D and 6E). Together, these data demonstrate that Inc-CTSLP4 overexpression inhibits the proliferative and metastatic capacity of GC cells in vivo.

DISCUSSION

Most GC patients diagnosed with advanced-stage disease present with cancer metastases, which leads to poor prognosis, less effective surgical treatment, and more resistant to drug therapy.24,25 Thus, there is an urgent need to explore more about the regulatory mechanisms underlying GC metastasis and to develop new therapeutic strategies. EMT describes a reversible phenotypic transformation from an epithelial form to a mesenchymal form and is a vital biological cellular process implicated in cancer metastasis, which could facilitate the adhesive and invasive ability of cells during the tumor development and progression.26,27 EMT could be regulated at multiple levels, including the epigenetic, transcriptional, posttranscriptional, translational, and posttranslational levels.27 lncRNAs have been demonstrated to affect gene regulation through various mechanisms and play important regulatory roles in tumorigenesis and cancer progression. In this study, we identify that Inc-CTSLP4 is a novel lncRNA in regulating GC cell EMT and metastasis and reveal that Inc-CTSLP4 is significantly downregulated in GC tissues, and low expression of Inc-CTSLP4 is positively correlated with advanced TNM stage, local invasion, lymph node metastasis, and poor prognosis. We further demonstrate that Inc-CTSLP4 significantly inhibits the metastatic potential of GC cells in vitro and in vivo by attenuating HNRNPAB-mediated Snail transcription. Our findings indicate that Inc-CTSLP4 is a novel EMT regulator in suppressing GC progression and could serve as an independent prognostic indicator and therapeutic target for metastatic GC.

LncRNAs mainly exert their functions upon formation of lncRNA-protein complexes. In this study we determine that Inc-CTSLP4 binds to Hsp90α. Hsp90α is an isoform of the Hsp90 family and has been shown to be upregulated in various human cancers.28–30 Recent studies have showed that Hsp90α, as a molecular chaperone, plays an important role in the post-translational conformational maturation, stabilization, and activation of numerous client proteins, many of which participate in signal transduction pathways that regulate proliferation, apoptosis, or metastasis of cancer cells.31,32 The Hsp90-client complexes vary in their forms, and increasing numbers of lncRNAs have been discovered to interact with Hsp90 and regulate their client proteins, leading to the term “Hsp90-associated LncRNAs”.33,34 In our study, integrative analysis including RNA-pull-down-mass spectrometry (MS) and RIP assays in GC cells identify

pGL3-Basic-SNAIL and pGL3-Basic-SNAIL-del (deletion at position –866 to –862 bp) constructs, along with the pRL-TK plasmid, were transfected into HGC27-HNRNPAB cells and HGC27-Vector cells, and then the relative luciferase activity was measured (**p < 0.01, ***p < 0.001). (E and F) Western blot (E) and densitometric analysis (F) of E-cadherin, N-cadherin, HNRNPAB, and Snail in MGC803 and AGS cells transfected with AV-CTSLP4, HNRNPAB-expressing vector, or Snail si-RNA (**p < 0.01, ***p < 0.001).
Inc-CTSLP4 as an Hsp90\-associated IncRNA, and binding of Inc-CTSLP4 to Hsp90\-HNRNPAB, thus leading to the degradation of HNRNPAB via recruiting E3 ubiquitin ligase ZFP91. HNRNPAB belongs to the sub-family of hnRNPs, and we find that HNRNPAB is a TF of Snail in GC cells and promotes GC cell EMT by activating Snail transcription, indicating that Inc-CTSLP4 (an Hsp90-associated IncRNA) and HNRNPAB (an Hsp90-client protein) form an important pathway in regulating EMT during GC progression. Consistently, HNRNPAB is upregulated in GC tissues and predicts shorter OS of patients with GC. Moreover, HNRNPAB rescues the suppressive effects of Inc-CTSLP4 in GC cells. Thus, our findings reveal a novel mechanism of EMT regulation and provide a potential approach in preventing GC metastasis by targeting the Inc-CTSLP4-HNRNPAB pathway.

Epigenetic modulation of regulators in the Snail-mediated EMT program by ncRNAs has been studied previously, which showed that biotherapeutics based on IncRNA was a promising strategy for both vaccines and protein replacement therapy. Here, we find that Inc-CTSLP4 is a powerful suppressor of EMT, which may serve as an alternative target to treat metastatic GC. Although the detailed regulation of Inc-CTSLP4 in GC cells needs further investigation, our findings indicate that the activation of Inc-CTSLP4, such as via small activating RNA (saRNA) or via adeno-associated virus (AAV), could block the combination of Hsp90z and HNRNPAB to inhibit the transcription of Snail and EMT in vivo; thus, Inc-CTSLP4 may provide an alternative approach to treat metastatic GC. This is also the focus of our further research.

In summary, our findings support a model in which high levels of Inc-CTSLP4 recruit ZFP91 (E3 ubiquitin ligase) and bind Hsp90z/HNRNPAB complex in normal gastric epithelial cells, which prevents Hsp90z from binding HNRNPAB and promotes the degradation of HNRNPAB (a TF of Snail). While in GC cells, where Inc-CTSLP4 expression was downregulated, the Hsp90z-HNRNPAB interaction is increased, causing the stable expression of HNRNPAB and subsequent activating transcription of Snail, which leads to EMT and GC metastasis (Figure 7). Our findings suggest that Inc-CTSLP4 represents an additional layer in the regulation of GC progression and may serve as a novel prognostic biomarker and therapeutic target in GC.

### MATERIALS AND METHODS

#### Cell culture and patient samples

GC cell lines HTB-103, AGS, and NCI-N87 used in our study were purchased from American Type Culture Collection (ATCC), and MGC803, MKN45, MKN28, HGC27, and GE-1 cell lines were purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All GC cell lines were authenticated by short tandem repeat analysis and had negative results for mycoplasma. HTB-103, AGS, NCI-N87, MKN45, MKN28, and HGC27 were cultured at 37°C in a humidified atmosphere of 5% CO₂ with 95% air.

### Table 2. Correlation between the clinicopathological features and expression of HNRNPAB

| Clinicopathologic parameters | Number of cases | HNRNPAB immunostaining | p value |
|-----------------------------|-----------------|------------------------|---------|
|                            |                 | Weak positive (n = 57) | Strong positive (n = 100) |
| Age (years)                |                 |                        |         |
| ≥60                        | 89              | 33                     | 56      | 0.818 |
| <60                        | 68              | 24                     | 44      |       |
| Gender                     |                 |                        |         |
| Male                       | 112             | 42                     | 70      | 0.623 |
| Female                     | 45              | 15                     | 30      |       |
| Tumor size (cm)            |                 |                        |         |
| ≥5                         | 102             | 31                     | 71      | 0.036 |
| <5                         | 55              | 26                     | 29      |       |
| Local invasion             |                 |                        |         |
| T1, T2                     | 18              | 8                      | 10      | 0.445 |
| T3, T4                     | 139             | 49                     | 90      |       |
| Lymph node metastasis      |                 |                        |         |
| No                         | 27              | 16                     | 11      | 0.006 |
| Yes                        | 130             | 41                     | 89      |       |
| TNM stage                  |                 |                        |         |
| I, II                      | 34              | 18                     | 16      | 0.023 |
| III, IV                    | 123             | 39                     | 84      |       |

Figure 5. HNRNPAB is inversely correlated with Inc-CTSLP4 in GC tissues and rescues the suppressive effects of Inc-CTSLP4 on GC cells

(A) Representative immunohistochemical staining of HNRNPAB in GC tumor tissues and adjacent non-tumor tissues (magnification: 200× and 400×). (B) The expression levels of HNRNPAB in 157 pairs of GC patients based on HNRNPAB IHC score (GC cohort 2, ***p < 0.001). (C) Validation of HNRNPAB expression in GEPIA. (D) The expression levels of HNRNPAB in GC patients with different pathological stages based on HNRNPAB IHC score (**p < 0.01, ***p < 0.001). (E) And (F) The correlation of HNRNPAB expression levels and overall survival in the GSE14210 dataset (n = 118) and GSE14210, GSE15459, GSE2377, GSE29272, and GSE51105 dataset (n = 592) was analyzed by Kaplan-Meier plotter. (G) Kaplan-Meier survival analysis for OS of 157 patients with GC (GC cohort 2) reveals a statistically significant difference between the low HNRNPAB expression group (n = 129) and the high HNRNPAB group (n = 28). (H and I) Univariate (H) and multivariate (I) analysis of for prognostic features of GC patients (n = 157) showed that the expression of HNRNPAB was an independent prognostic factor for survival. (J) HNRNPAB is downregulated in the high Inc-CTSLP4 expression group compared to the low Inc-CTSLP4 expression group (GC cohort 2, **p < 0.01). (K and L) Correlation analysis of HNRNPAB with E-cadherin (K) or N-cadherin (L) in GC. (M and N) Validation of the relationship between HNRNPAB and E-cadherin (M) or Snail (N) based on GEPIA. (O–R) The metastatic abilities of GC cells (MGC803 and HGC27) after overexpression or shRNA knockdown of HNRNPAB (Transwell assays, magnification: 200×). (S and T) The metastatic abilities of GC cells (MGC803 and AGS cells) transfected with Inc-CTSLP4, HNRNPAB-expressing vector, or Snail si-RNA (Transwell assays, magnification: 200×, ***p < 0.001).
RPMI-1640 medium (Gibco, San Francisco, CA, USA) containing 10% fetal bovine serum (Gibco) with 100 U/mL penicillin and 100 U/mL streptomycin (Sangon Biotec, Shanghai, China).

GES-1 and MGC-803 were cultured at 37°C in a humidified atmosphere of 5% CO₂ with DMEM medium (Gibco) containing 10% fetal bovine serum with 100 U/mL penicillin and 100 U/mL streptomycin.

A total of 200 patients in this study underwent D2 gastrectomy at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine between 2011 and 2016. All the samples were obtained with the patients’ informed consent and were histologically confirmed. Forty-three pairs of GC tumor tissues and adjacent non-tumor tissues (GC cohort 1) were stored in RNA-latter reagent at −80°C for RNA extraction, and another 157 paired GC tumor tissues and adjacent non-tumor tissues (GC cohort 2) were fixed with formalin and made into tissue microarrays.

**Plasmid construction, virus production, and infection**

Full-length lnc-CTSLP4 sequence obtained by RACE analysis was constructed to a pAV-MCMV-EGFP-3FLAG vector using Ready-to-Use Seamless Cloning Kit (Sangon, Shanghai, China). Adenoviruses AV-CTSLP4 and AV-CON were generated in HEK293A cells and purified by cesium chloride (CsCl) density-gradient ultracentrifugation. Adenoviruses were added into the culture medium of HGC-27 and MGC-803 2 days before further experiments. shRNA sequences targeting lnc-CTSLP4 were designed by BLOCK-iT RNAi Designer (https://rnaidesigner.thermosher.com/rnaexpress/sort.do) and constructed

![Figure 6. Lnc-CTSLP4 overexpression inhibits GC cell invasion and metastasis in vivo](image-url)
to pLKO.1-puro plasmid. The lentiviruses were generated by co-transfected shRNA plasmid with pSAX2 and pMD2.G plasmid to 293T cells. Lentivirus was precipitated by ultra-speed centrifugation. ShRNA lentivirus was added to the supernatant of HGC-27 and MGC-803 cells, and puromycin was used for screening stable clones.

**RNA extraction, qRT-PCR, and RACE**

Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA, USA) and was reversely transcribed into cDNA using Reverse Transcription system (Toyobo, Kita-ku, Osaka, Japan). qRT-PCR was performed to quantify CTSLP4 mRNA level with the SYBER Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). The primers for the PCR reaction are listed in Table S3. The 2-ΔΔCt method was used to calculate the relative abundance of RNA normalized to GAPDH. 5'-RACE and 3'-RACE analyses of CTSLP4 were performed using a GeneRacer Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s manual. The primers for the qRT-PCR reaction and RACE are listed in Table S3.

**Western blot**

Cells were lysed using RIPA lysis buffer (Solarbio, Beijing, China) with proteinase inhibitor cocktail (Sigma, St. Louis, MO, USA) and phosphatase inhibitor cocktail II and III (Sigma). The concentration of protein lysates was detected by BCA protein concentration detection kit (Thermo Fisher, San Francisco, CA, USA). A total of 30 μg protein is used at each Western blot. The protein was loaded to vertical electrophoresis and transferred to a 0.22 μm polyvinylidene fluoride (PVDF) membrane. The membrane was incubated with primary antibody and subsequent secondary antibody. The bands were detected by a Tanon ECL imaging system. ImageJ software was used to quantify the immunoblots. Area, mean gray value, and integrated density of immunoblots were measured during the process. For detailed description and the antibodies used this process, see Table S4.

**IP and Co-IP**

IP and Co-IP were performed using a magnetic Co-IP kit (Thermo Fisher, San Francisco, CA, USA) according to its user guide. Briefly, a total of 1 × 10^7 cells were seeded in a 10 cm plate, and 500 μL IP lysis buffer was used to obtain the cell lysate. After centrifugation, cell lysate was added with 5 μL magnetic beads pre-coupled with primary antibody and incubated at room temperature for 1 h. After washing with IP lysis buffer and followed by ultrapure water, the protein-protein complex was eluted from the magnetic beads with Elution buffer. After adding SDS loading buffer (Thermo Fisher), denaturation of the protein samples were performed at 100 degree for 10 minutes. The protein samples were then subjected to further analysis.

**IHC staining and FISH**

For IHC staining, the slides were incubated at 60°C for 60 min and immersed in xylene for 10 min. After that, the slides were soaked sequentially in anhydrous ethanol, 95% ethanol, and 75% ethanol for 5 min. Then the slides were incubated in 0.01 M sodium citrate solution for 15 min. After H2O2 incubation and sheep serum incubation, a primary antibody was added to the slides, and they were incubated at 4°C overnight. After incubation of horseradish peroxidase (HRP)-labeled secondary antibody, the slices were treated with DAB and hematoxylin. The resin was added and covered with a glass slide. Three pathologists evaluated the staining separately. The staining intensity and percentage were used to score the overall tissue sections. The intensity was graded as follows: 0 points (no staining), 1 point (light-brown staining), 2 points (brown staining), and 3 points (dark-brown staining). The primary antibody number was divided into four grades: 0 points (no staining), 1 point (light-brown staining), 2 points (brown staining), and 3 points (dark-brown staining). Staining score was calculated as follows: overall staining score = intensity score × percentage score. A final score ≤ 3 was considered as negative staining and >3 as positive staining. The antibodies used are listed in the Supplemental information.

For FISH staining, the paraffin sections were taken out and sequentially put into xylene-xylene II-anhydrous alcohol-I-anhydrous alcohol II-85% alcohol-75% alcohol 5 min-diethyl pyrocarbonate (DEPC) water. The slides were boiled in the repair fluid and cooled naturally. They were digested for 25 min by adding protease K (20 μg/mL) at 37°C. After adding pre-hybrids, the Inc-CTSLP4 probe

![Diagram of Normal and Tumor](image-url)
hybridization solution-containing probe was added to the slides. The slides were incubated at 37°C overnight. Then the slides were added sequentially with 2 × SSC for 37°C wash 10 min, 1 × SSC for 37°C wash 25 min, and 0.5 × SSC for room temperature wash 10 min. The slides were dripped with 2-(4-Amidinophenyl)-6-indolecarbamine dihydrochloride (DAPI) dye and incubated for 8 min. After washing, the anti-fluorescence quenching tablets were dripped. The images were observed and collected under a fluorescence microscope. The intensity was graded as follows: percentage of positive cell number was divided into four grades: 0 points (<5%), 1 point (5%–30%), 2 points (31%–50%), and 3 points (51%–100%). Percentage score ≤1 was considered as negative staining or weakly positive staining (low lnc-CTSLP4 expression) and ≥2 as strongly positive staining (high lnc-CTSLP4 expression).

**RNA pulldown and MS analysis**

**In vitro** transcription of lnc-CTSLP4 full-length sense, antisense, and serial truncated sequences were performed using T7 or SP6 RNA Polymerase (New England Biolabs, Ipswich, Suffolk, England) according to the manufacturer’s instructions (T7 RNA polymerase was used to perform **in vitro** transcription of lnc-CTSLP4 full-length sense and SP6 RNA polymerase was used for lnc-CTSLP4 full-length antisense). RNA pulldown assays were performed with the Pierce Magnetic RNA-Protein Pull-Down Kit according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA). IncRNA-interacting proteins were obtained and subjected to MS analysis. LC-MS/MS detection was carried out on a hybrid quadrupole-TOF mass spectrometer (TripleTOF 5600+, SCIEX) equipped with a nanoLC system (nanoLC-Ultra 1D Plus, Eksigent).

**RIP assays**

RIP experiments were performed by using an RNA binding protein IP kit (Millipore). Generally, adherent cells were collected by RNase-free scraps and re-suspended in RIP lysis buffer. After freeze and thaw cycle to swell the cells, the RNA-protein complex was IP by magnetic beads pre-coupled with antibodies or immunoglobulin G (IgG) isotype. After washing with RIP wash buffer, the RNAs captured were extracted by phenol-chloroform-isooamyliccohol (125:25:1) extraction and were reverse transcribed to cDNA. RT-PCR was used for the detection of the protein-binding RNAs.

**ChIP assays**

ChIP assays were performed using a Simple ChIP Plus Enzymatic Chromatin IP Kit according to the manufacturer’s instructions (Cell Signaling Technology, Beverly, MA, USA). Briefly, cells were cross-linked by formalin and collected into an Eppendorf tube. After ultra-sonication, the chromosome was broken into small fragments. The lysates were added by primary antibody and stored at 4°C overnight. A total of 5 μg antibodies were used in 100 μL lysate originated from 1 × 10^6 cells in one experiment. Protein A/G beads were added into the lysate to capture antibody-protein-DNA complex. After centrifugation and washing, the DNA sequences were obtained by reverse-crosslinking and purification. Quantification of ChIP DNA was performed using qPCR. ChIP data were calculated as percentages relative to the input DNA using the equation: 2(Input Ct − Target Ct) × 100 (%). The primers used in QRT-PCR are listed in Table S3.

**Dual-luciferase reporter assay**

Full-length DNA sequences and mutated DNA sequence were synthesized and constructed to pGL3-basic plasmid via Ready-to-Use Seamless Cloning Kit (Sangon). pCDNA3.1-HNRNPAB plasmid was purchased from PPL (Nanjing, China). HGC27-vector and HGC27-HNRNPAB cells were obtained by transfecting with pCDNA3.1-HNRNPAB or pDNA 3.1 plasmids to HGC-27 using Lipofectamine 3000 Transfection Reagent (Invitrogen). G418 was used to select stable clones. For dual-luciferase reporter assay, HGC27-vector and HGC27-HNRNPAB cells were seeded in 24-well plates and transfected with pGL3-Basic-SNAIL, pGL3-Basic-SNAIL(del), and pRL-TK plasmid using a Lipofectamine 3000 Transfection Reagent. Three days after transfection, dual-luciferase reporter assay was performed using Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer’s instructions.

**GST pulldown assay**

6 × His tag sequences followed by CDS sequence of HSP90AA1 were synthesized and constructed to PET24a (+) plasmid. GST tag sequences followed by CDS of HNRNPAB were synthesized and constructed to pGEX-4T-1 plasmid. pET28a-HSP90AA1 or pGEX-4T-1-HNRNPAB plasmid was transformed to BL21(DE3) E. coli. IPTG was used to induce the expression of His-HSP90AA1 and GST-HNRNPAB. After incubation and collection, 400 μL Ni-IDA binding buffer was used to re-suspend the bacteria. Ultrasound sonication was used to release the intracellular proteins. The fusion proteins were purified by Ni-IDA-Sepharose CL-6B affinity chromatography column. After washing and elution, the proteins were subjected to further analysis.

The GST pulldown assays were performed using Pierce GST Protein Interaction Pulldown Kit (Thermo) as per its instructions. Briefly, 100 μg GST tag (Sangon, Shanghai, China) or GST-HNRNPAB was immobilized to 50 μL glutathione agarose (50% concentration). 800 μL pulldown-lysis buffer with 100 μg His-HSP90AA1 was added to immobilized GST or GST-HNRNPAB protein. After incubation at 4°C for 1 h, the uncaptured proteins were washed, and the captured proteins were eluted by glutathione elution buffer. The samples obtained were subjected to Western blot analysis. The materials used are listed in Table S4.

**Cell migration and invasion assay**

For the migration assay, cells were suspended in serum-free medium (1 × 10^5 cells/insert) and added to the upper chamber of the 24-well insert (membrane pore size, 8 μm; Corning Life Sciences, MA, USA). Medium containing 10% serum was added to the lower chamber. After incubation for 12 h, the cells that migrated to the bottom of the membranes were fixed and stained with 0.1% crystal violet for 30 min. For the invasion assay, chamber membranes were coated with diluted Matrigel (BD Bioscience, San Jose, CA, USA). After incubation for 24 h, the cells that invaded to the bottom of the membrane were fixed and stained with 0.1% crystal violet for 30 min.
The stained cells were counted using a microscope and photographed. Ten fields were randomly selected to count, and the average number was presented.

**In vivo tumorigenesis and peritoneal dissemination**

Four-week-old male BALB/c nude mice were purchased from Institute of Zoology Chinese Academy of Science and housed at a specific pathogen-free environment in the Animal Laboratory Unit, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China. MGC803 cells transduced by AV-CTSLP4 or AV-CON adenoviral particles (2 × 10^6) were harvested and resuspended in 500 μL of PBS and then were injected subcutaneously or peritoneally into the mice (4 × 10^6/100 μL PBS/mouse). HGC27 cells transduced by sh-CTSLP4 or sh-Ctrl lentivirus (2 × 10^7) were harvested and resuspended in 500 μL of PBS and then were injected subcutaneously into the mice (4 × 10^6/100 μL PBS/mouse). For tumorigenesis *in vivo*, all mice were sacrificed after 28 days, and the subcutaneous lump was removed, imaged, and placed into 4% formaldehyde for paraffin embedding. For the peritoneal dissemination model, all mice were sacrificed after 30 days and peritoneal metastasis nodules were counted.

**Statistical analysis**

All experiments were repeated at least three times and the results were summarized as means ± SD. The Student t test and one-way analysis of variance (ANOVA) were used to analyze the data, and chi-square tests were used to analyze categorical variables. All statistical tests were performed with SPSS 16.0 (SPSS, Chicago, IL, USA), and p values <0.05 were regarded as indicating statistically significant differences (*p < 0.05, **p < 0.01, ***p < 0.001).

**Availability of data and materials**

All data and details can be obtained by contacting the corresponding author.

**Ethics approval and consent to participate**

The experimental protocol for animal studies was reviewed and approved by Ruijin Hospital Institutional Ethics Committee.

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at [https://doi.org/10.1016/j.omtn.2021.02.003](https://doi.org/10.1016/j.omtn.2021.02.003)

**ACKNOWLEDGMENTS**

We thank LetPub ([https://www.letpub.com/](https://www.letpub.com/)) for the linguistic assistance during the preparation of this manuscript. This work was supported by the National Natural Science Foundation of China (Nos. 81871902 to L.S., 81772509 to B.L., and 81772518 to Z. Yang); the Multicenter Clinical Trial of Shanghai Jiao Tong University School of Medicine (No. DLY201602 to Z.Z.); the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20152505 to L.S.); and the Eagle Program to Young Doctors of Shanghai Anticancer Association (No. SACA-CY19C10 to Z. Yu).

**AUTHOR CONTRIBUTIONS**

L.S. and B.L. made the original proposal and designed and supervised the project; T.P., Z. Y., and Z.J. performed all the experiments; T.P. and X.W. performed data analysis; all participated in data interpretation; T.P. and Z.Y. prepared the first draft; L.S. and B.L. completed the final revisions. All authors read and approved the final manuscript.

**DECLARATION OF INTERESTS**

The authors declare no competing interests.

**REFERENCES**

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424.
2. Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X.Q., and He, J. (2016). Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115–132.
3. Bernardos, N., Greemers, G.J., Nieuwenhuijzen, G.A., Boscha, K., Pruinj, J.F., and Lemmens, V.E. (2013). No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann. Oncol. 24, 3056–3060.
4. Wagner, A.D., Syn, N.L., Moehler, M., Grothe, W., Yong, W.P., Tai, B.C., Ho, J., and Unverzagt, S. (2017). Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 8, CD004864.
5. Chaffer, C.L., and Weinberg, R.A. (2011). A perspective on cancer cell metastasis. Science 331, 1559–1564.
6. Chambers, A.F., Groom, A.C., and MacDonald, I.C. (2002). Dissemination and tumorigenesis; T.P. and Z.Y. prepared the first draft; L.S. and B.L. completed the final revisions. All authors read and approved the final manuscript.

**DECLARATION OF INTERESTS**

The authors declare no competing interests.

**REFERENCES**

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424.
2. Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X.Q., and He, J. (2016). Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115–132.
3. Bernardos, N., Greemers, G.J., Nieuwenhuijzen, G.A., Boscha, K., Pruinj, J.F., and Lemmens, V.E. (2013). No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann. Oncol. 24, 3056–3060.
4. Wagner, A.D., Syn, N.L., Moehler, M., Grothe, W., Yong, W.P., Tai, B.C., Ho, J., and Unverzagt, S. (2017). Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 8, CD004864.
5. Chaffer, C.L., and Weinberg, R.A. (2011). A perspective on cancer cell metastasis. Science 331, 1559–1564.
6. Chambers, A.F., Groom, A.C., and MacDonald, I.C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563–572.
7. Yeung, K.T., and Yang, J. (2017). Epithelial-mesenchymal transition in tumor metastasis. Mol. Oncol. 11, 28–39.
8. Nieto, M.A. (2013). Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342, 1234850.
9. Diemahr, M., and Christofori, G. (2016). Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr. Opin. Cell Biol. 43, 7–13.
10. Grau, Y., Carteret, C., and Simpson, P. (1984). Mutations and Chromosomal Rearrangements Affecting the Expression of Snail, a Gene Involved in Embryonic Patterning in DROSOPHILA MELANOGASTER. Genetics 108, 347–360.
11. Lin, Y., Dong, C., and Zhou, B.P. (2014). Epigenetic regulation of EMT: the Snail story. Curr. Pharm. Des. 20, 1608–1705.
12. Skrzypek, K., and Majka, M. (2020). Interplay among SNAIL Transcription Factor, MicroRNAs, Long Non-Coding RNAs, and Circular RNAs in the Regulation of Tumor Growth and Metastasis. Cancers (Basel) 12, 209.
13. Wang, Y., Shi, J., Chai, K., Ying, X., and Zhou, B.P. (2013). The Role of Snail in EMT and Tumorigenesis. Curr. Cancer Drug Targets 13, 963–972.
14. Kopp, F., and Mendell, J.T. (2018). Functional Classification and Experimental Dissection of Long Noncoding RNAs. Cell 172, 395–407.
15. Zhang, C.Y., Li, R.K., Qi, Y., Li, X.N., Yang, Y., Liu, D.L., Zhao, J., Zhu, D.Y., Wu, K., Zhou, X.D., and Zhao, S. (2016). Upregulation of long noncoding RNA SPRY4-IT1 promotes metastasis of esophageal squamous cell carcinoma via induction of epithelial-mesenchymal transition. Cell Biol. Toxicol. 32, 391–401.
16. Sakai, S., Ohbata, T., Kitagawa, K., Uchida, C., Aoshima, T., Niiida, H., Suzuki, T., Inoue, Y., Miyazawa, K., and Kitagawa, M. (2019). Long Noncoding RNA ELIT-1 Acts as a Smad3 Cofactor to Facilitate TGFβ/Smad Signaling and Promote Epithelial-Mesenchymal Transition. Cancer Res. 79, 2821–2838.
17. Xiong, H.G., Li, H., Xiao, Y., Yang, Q.C., Yang, L.L., Chen, L., Bu, L.L., Zhang, W.F., Zhang, J.L., and Sun, Z.J. (2019). Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma. J. Exp. Clin. Cancer Res. 38, 278.
18. Li, H., Yu, B., Li, J., Su, L., Yan, M., Zhu, Z., and Liu, B. (2014). Overexpression of IncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 5, 2318–2329.

19. Kalluri, R., and Weinberg, R.A. (2009). The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420–1428.

20. Dongre, A., and Weinberg, R.A. (2019). New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69–84.

21. Hoter, A., El-Sabban, M.E., and Naim, H.Y. (2018). The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease. Int. J. Mol. Sci. 19, 2560.

22. Xu, S.H., Zhu, S., Wang, Y., Huang, J.Z., Chen, M., Wu, Q.X., He, Y.T., Chen, D., and Yan, G.R. (2018). ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation. Cell Death Dis. 9, 479.

23. Zhou, Z.J., Dai, Z., Zhou, S.L., Hu, Z.Q., Chen, Q., Zhao, Y.M., Shi, Y.H., Gao, Q., Wu, W.Z., Qiu, S.J., et al. (2014). HNRNPAB induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by transcriptionally activating SNAIL. Cancer Res. 74, 2750–2762.

24. Zhao, J., Liu, Y., Zhang, W., Zhou, Z., Wu, J., Cui, P., Zhang, Y., and Huang, G. (2015). Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer. Cell Cycle 14, 3112–3123.

25. Peng, Z., Wang, C.X., Fang, E.H., Wang, G.B., and Tong, Q. (2014). Role of epithelial-mesenchymal transition in gastric cancer initiation and progression. World J. Gastroenterol. 20, 5403–5410.

26. Bill, R., and Christofori, G. (2015). The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett. 589, 1577–1587.

27. Cao, Q.H., Liu, F., Li, C.Z., Liu, N., Shu, M., Lin, Y., Ding, L., and Xue, L. (2018). Testes-specific protease 50 (TSP50) promotes invasion and metastasis by inducing EMT in gastric cancer. BMC Cancer 18, 94.

28. Elzakra, N., Cui, L., Liu, T., Li, H., Huang, J., and Hu, S. (2017). Mass Spectrometric Analysis of SOX11-Binding Proteins in Head and Neck Cancer Cells Demonstrates the Interaction of SOX11 and HSP90a. J. Proteome Res. 16, 3961–3968.

29. Lee, Y.C., Chang, W.W., Chen, Y.Y., Tsai, Y.H., Chou, Y.H., Tseng, H.C., Shen, H.L., Wu, C.C., Chang-Chien, J., Lee, H.T., et al. (2017). Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2. Int. J. Mol. Sci. 18, 1986.

30. Jiang, H., Duan, B., He, C., Geng, S., Shen, X., Zhu, H., Sheng, H., Yang, C., and Gao, H. (2014). Cytoplasmic HSP90α expression is associated with perineural invasion in pancreatic cancer. Int. J. Clin. Exp. Pathol. 7, 3305–3311.

31. Cullinan, S.B., and Whitesell, L. (2006). Heat shock protein 90: a unique chemotherapeutic target. Semin. Oncol. 33, 457–465.

32. Trepel, J., Mollapour, M., Giaccone, G., and Neckers, L. (2010). Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537–549.

33. Zhou, C.C., Yang, F., Yuan, S.X., Ma, J.Z., Liu, F., Yuan, J.H., Bi, F.R., Lin, K.Y., Yin, J.H., Cao, G.W., et al. (2016). Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. Hepatology 63, 850–863.

34. Guo, H., Zhao, L., Shi, B., Rao, J., Zheng, D., Zhou, B., and Shi, J. (2018). GALNT5 uARNA promotes gastric cancer progression through its interaction with HSP90. Oncogene 37, 4505–4517.

35. Chen, D.D., Cheng, J.T., Chandoor, A., Sun, X.W., Zhang, L., Lu, M.D., Sun, W.J., and Huang, Y.P. (2019). microRNA-33a prevents epithelial-mesenchymal transition, invasion, and metastasis of gastric cancer cells through the Snail/Slug pathway. Am. J. Physiol. Gastrointest. Liver Physiol. 317, G147–G160.
Supplemental information

Tumor suppressor Inc-CTSLP4 inhibits EMT and metastasis of gastric cancer by attenuating HNRNPAB-dependent Snail transcription

Tao Pan, Zhenjia Yu, Zhijian Jin, Xiongyan Wu, Airong Wu, Junyi Hou, Xinyu Chang, Zhiyuan Fan, Jianfang Li, Beiqin Yu, Fangyuan Li, Chao Yan, Zhongyin Yang, Zhenggang Zhu, Bingya Liu, and Liping Su
Supplementary Figure S1: Rapid amplification of the cDNA ends of Lnc-CTSLP4.
A: The total RNAs used for RACE (RT-PCR assays and A260/A280).
B: The identified fraction of Lnc-CTSLP4 (RT-PCR).
C: 5’-rapid amplification of cDNA ends of Lnc-CTSLP4.
D: 3’-rapid amplification of the cDNA ends of Lnc-CTSLP4.
E: The schematic depicting the gene locus and the primer locations of RACE.
F: The full sequence of Lnc-CTSLP4 in HGC27 cells.
Supplementary Figure S2: Association between Lnc-CTSLP4 expression and clinicopathological features in GC tissues. A: Representative images of Lnc-CTSLP4 FISH staining in GC tumor tissues from different group. Scale bars: 100 μm and 200μm. B: Relationship between Lnc-CTSLP4 expression level and local invasion, TNM stage and lymph node metastasis. *p < 0.05, ***p < 0.001.
Supplementary Figure S3: The influence of Lnc-CTSLP4 on EMT progression based on IF analysis. **A:** Representative images of E-Cadherin, N-Cadherin and Snail IF staining in HGC27-sh-Ctrl and HGC27-sh-CTSLP4 cells (Magnification: 400×). **B:** Representative images of E-Cadherin, N-Cadherin and Snail IF staining in MGC803-AV-CON and MGC803-AV-CTSLP4 cells (Magnification: 400×).
Supplementary Figure S4: Treatment with an Hsp90 inhibitor (17-AAG) results in decreased HNRNPAB expression. A-B: The protein expression of HNRNPAB and Hsp90α in a dose-dependent and time-dependent manner after 17-AAG treatment. C-D: The mRNA expression of HNRNPAB in a dose-dependent and time-dependent manner after 17-AAG treatment. ns p > 0.05, ***p < 0.001.
Supplementary Figure S5: The predicted Lnc-CTSLP4–Hsp90α interaction and RNA secondary structure of Lnc-CTSLP4. **A:** The potential interaction of Lnc-CTSLP4 and Hsp90α predicted by CatRAPID (http://service.tartaglialab.com/page/catrapid_group). The x- and the y-axes represent the indexes of the RNA and protein sequences, respectively. **B:** The potential binding region of Lnc-CTSLP4 and Hsp90α (TOP10, ranked by Normalized Score). **C:** The predicted RNA secondary structure of Lnc-CTSLP4 via RNAfold web server (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi). **D:** Mountain plot representation of the MFE structure, the thermodynamic ensemble of RNA structures, the centroid structure and the positional entropy for each position.
Supplementary Figure S6: HNRNPAB is overexpressed in GC and associated with local invasion, lymph node metastasis, tumor size and poor survival. A-C: Relationship between HNRNPAB level and local invasion (A), lymph node metastasis (B) and tumor size (C). *p < 0.05. D-E: Kaplan–Meier survival plots analysis of the
correlation between high HNRNPAB expression levels and worse FP (First Progression) in the GSE14210 dataset (n=118) (D) and GSE14210, GSE15459, GSE22377, GSE29272 and GSE51105 dataset (n=358) (E). **F-G:** Kaplan–Meier survival plots analysis of the correlation between high HNRNPAB expression levels and worse PPS (Post Progression Survival) in the GSE14210 dataset (n=114) (F) and GSE14210, GSE15459, GSE22377, GSE29272 and GSE51105 dataset (n=221) (G).
Supplementary Figure S7: Lnc-CTSLP4 overexpression inhibits GC cell growth in vivo. 

**A-B**: The effect of CTSLP4 overexpression on tumor growth in nude mice. MGC803-AV-CON or MGC803-AV-CTSLP4 cells were subcutaneously injected into nude mice, and tumor volumes were calculated every 7 days. *p < 0.05. 

**C**: Photographs of tumors derived from MGC803-AV-CON and MGC803-AV-CTSLP4 cells in nude mice (N=5 per group). 

**D**: Weight of tumors derived from MGC803-AV-CON or MGC803-AV-CTSLP4 cells. **p < 0.01. 

**E-F**: The effect of CTSLP4 knockdown on tumor growth in nude mice. HGC27-sh-Ctrl and HGC27-sh-CTSLP4
cells were subcutaneously injected into nude mice, and tumor volumes were calculated every 7 days. **p < 0.01, ***p < 0.001. **G:** Photographs of tumors derived from HGC27-sh-Ctrl and HGC27-sh-CTSLP4 cells in nude mice (N=5 per group). **H:** Weight of tumors derived from HGC27-sh-Ctrl and HGC27-sh-CTSLP4 cells. **p < 0.01.